Favipiravir Experience in COVID-19 Patients at a Tertiary Center Intensive Care Unit
C Ovid-19, Sultan Acar Sevinc, Ayse Surhan Cin, Nermin Balta Basi, Seyhan Metin, Tugba Yucel, Serkan Islamoglu, Mustafa Altinay, Haci Mustafa Ozdemir, Etfal Sisli, Hospital
SiSli Etfal Hastanesi Tip Bulteni / The Medical Bulletin of Sisli Hospital, doi:10.14744/semb.2021.35902
is the disease caused by severe acute respira- tory syndrome coronavirus 2 (SARS-CoV-2) infection and may present in different clinical scenarios: About 80% of patients present with mild, 13.8% present with severe disease, and 6.1% with critical disease. [1] According to the guidelines published by the Ministry of Health in Turkey, patients with severe and critical disease were advised to be admitted to intensive care unit (ICU). [2] Turkey diagnosed Objectives: The aim of this study was to compare intensive care unit (ICU) and overall hospital mortality in patients treated with favipiravir and lopinavir-ritonavir for COVID-19. Methods: Data were collected retrospectively between March 10 and May 10, 2020, from patients' records admitted to ICU due to COVID-19. Laboratory data, clinical characteristics, ICU and hospital mortality, ICU and hospital length of stay were compared in patients treated with favipiravir and lopinavir-ritonavir. Results: A total of 100 patients' data were investigated. Favipiravir was used as the treatment for 85% of patients, with the rest treated with lopinavir-ritonavir. Clinical and laboratory data of both antiviral treatment groups were similar. Length of hospital stay was 16 (9-24) days with favipiravir and 8.5 (5-12.5) days with lopinavir-ritonavir (p=0.002). Length of ICU stay for favipiravir and lopinavir-ritonavir groups were 8 (5-15) days and 4 (3-9) days, respectively (p=0.011). ICU mortality was 65.9% for the favipiravir and 80% for lopinavir-ritonavir (p=0.002). Hospital mortality for favipiravir and lopinavir-ritonavir was 67.1% and 80%, respectively (p=0.001).
Conclusion: The mortality in patients treated with favipiravir was less than patients treated with lopinavir-ritonavir. Favipiravir needs more attention and trials for its effect to be confirmed.
References
Bhatraju, Ghassemieh, Nichols, Kim, Jerome et al., Covid-19 in critically Ill patients in the Seattle regioncase series, N Engl J Med,
doi:10.1056/NEJMoa2004500Cai, Yang, Liu, Chen, Shu et al., Experimental treatment with favipiravir for COVID-19: An open-label control study, Engineering,
doi:10.1016/j.eng.2020.03.007Du, Chen, Favipiravir: Pharmacokinetics and concerns about clinical trials for 2019-nCoV infection, Clin Pharmacol Ther,
doi:10.1002/cpt.1844Grasselli, Zangrillo, Zanella, Antonelli, Cabrini et al., Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy, JAMA,
doi:10.1001/jama.2020.5394Ilhan, Altuntas, Optimum management of COVID-19 in the geriatric population: The need for a comprehensive assessment
Kupferschmidt, Cohen, WHO launches global megatrial of the four most promising coronavirus treatments
Mitra, Fergusson, Lloyd-Smith, Wormsbecker, Foster et al., Baseline characteristics and outcomes of patients with COVID-19 admitted to intensive care units in Vancouver, Canada: a case series, CMAJ,
doi:10.1503/cmaj.200794Pascarella, Strumia, Piliego, Bruno, Buono et al., COVID-19 diagnosis and management: a comprehensive review, J Intern Med,
doi:10.1111/joim.13091Stringer, Puskarich, Kenes, Dickson, COVID-19: The uninvited guest in the intensive care unit -implications for pharmacotherapy, Pharmacotherapy,
doi:10.1002/phar.2394Wang, Hu, Hu, Zhu, Liu et al., Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirusinfected pneumonia in Wuhan, China, JAMA,
doi:10.1001/jama.2020.1585Yamamoto, Matsuyama, Hoshino, Yamamoto, Nelfinavir inhibits replication of severe acute respiratory syndrome coronavirus 2 in vitro, bioRxiv,
doi:10.1101/2020.04.06.026476Zheng, Sun, Xu, Pan, Zhang et al., Clinical characteristics of 34 COVID-19 patients admitted to intensive care unit in Hangzhou, China, J Zhejiang Univ Sci B,
doi:10.1631/jzus.B2000174{ 'indexed': {'date-parts': [[2022, 3, 29]], 'date-time': '2022-03-29T14:01:08Z', 'timestamp': 1648562468806},
'reference-count': 0,
'publisher': 'Kare Publishing',
'content-domain': {'domain': [], 'crossmark-restriction': False},
'published-print': {'date-parts': [[2021]]},
'DOI': '10.14744/semb.2021.35902',
'type': 'journal-article',
'created': {'date-parts': [[2021, 9, 22]], 'date-time': '2021-09-22T07:37:37Z', 'timestamp': 1632296257000},
'source': 'Crossref',
'is-referenced-by-count': 0,
'title': 'Favipiravir Experience in COVID-19 Patients at a Tertiary Center Intensive Care Unit',
'prefix': '10.14744',
'author': [{'given': 'Sultan', 'family': 'Acar Sevinc', 'sequence': 'first', 'affiliation': []}],
'member': '5966',
'published-online': {'date-parts': [[2021]]},
'container-title': 'SiSli Etfal Hastanesi Tip Bulteni / The Medical Bulletin of Sisli Hospital',
'original-title': [],
'deposited': { 'date-parts': [[2021, 9, 22]],
'date-time': '2021-09-22T07:37:39Z',
'timestamp': 1632296259000},
'score': 1,
'resource': {'primary': {'URL': 'https://sislietfaltip.org/jvi.aspx?un=SETB-35902&volume='}},
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[2021]]},
'references-count': 0,
'URL': 'http://dx.doi.org/10.14744/SEMB.2021.35902',
'relation': {},
'ISSN': ['1302-7123'],
'container-title-short': 'Sisli Etfal',
'published': {'date-parts': [[2021]]}}
